Prelude Therapeutics

58 articles about Prelude Therapeutics

• Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

  4/9/2024

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced the presentation of new preclinical data at the American Association for Cancer Research Annual Meeting for its highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation oral CDK4/6 inhibitor.

• PreludeDx™ to Present New Data in DCIS and Early-Stage Invasive Breast Cancer at the American Society of Breast Surgeons Annual Meeting

  4/3/2024

  Prelude Corporation announced that data will be highlighted in a Quickshot Scientific Session and poster presentation at the 25th American Society of Breast Surgeons Annual Meeting, to be held on April 10 - 14, 2024 at the Orlando World Center Marriott.

• Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

  3/5/2024

  Prelude Therapeutics Incorporated announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024, taking place from April 5 to 10, 2024.

• Prelude Therapeutics to Participate in Barclays Global Healthcare Conference - February 29, 2024

  2/29/2024

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024.

• Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

  2/15/2024

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.

• Prelude Therapeutics Announces $25 Million Private Placement

  12/11/2023

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company.

• Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

  11/1/2023

  Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.

• Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

  10/14/2023

  Prelude Therapeutics Incorporated announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA.

• Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September 2023

  8/29/2023

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that company executives will participate in three upcoming healthcare investment conferences.

• PreludeDx Appoints Dr. Leona Hamrick as Senior Director, Medical Affairs

  8/3/2023

  Prelude Corporation, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the appointment of Dr. Leona Hamrick DHSc, PA-C, MSL-BC to the newly created position of Senior Director, Medical Affairs.

• Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

  8/3/2023

  Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

• Prelude Therapeutics To Participate in Jefferies Healthcare Conference

  5/31/2023

  Prelude Therapeutics Incorporated announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 2023.

• Prelude Therapeutics Announces Pricing of Public Offering

  5/18/2023

  Prelude Therapeutics Incorporated today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,222 shares of its non-voting common stock, each at a price to the public of $5.75 per share, and, in lieu of common stock to investors who so choose.

• Prelude Therapeutics Announces Launch of Proposed Public Offering - May 17, 2023

  5/17/2023

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock.

• Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

  5/8/2023

  Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress.

• Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

  4/27/2023

  Prelude Therapeutics Incorporated today announced that company executives will participate in three upcoming healthcare investment conferences.

• Prelude Therapeutics to Present at American Association for Cancer Research 2023 ConferenceEight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline

  4/11/2023

  Prelude Therapeutics Incorporated today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

• Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

  3/15/2023

  Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update.   

• Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

  3/15/2023

  Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in hematologic malignancies.

• Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

  3/1/2023

  Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023.